Agresta Samuel 4

What Happened Samuel Agresta, Chief Medical Officer of OnKure Therapeutics (OKUR), was granted a derivative award covering 110,000 shares on 2026-04-01. The Form 4 reports an acquisition at $0.00 per share (derivative security), indicating an option-style award rather than an open-market purchase. This is a compensation grant subject to vesting, not an immediate ownership transfer or sale.

Key Details

• Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (timely filing).
• Reported transaction type: Derivative acquisition / award (listed as “A” on the Form 4).
• Award amount: 110,000 shares (reported at $0.00 per share on the filing).
• Vesting: 1/48th of the shares subject to the option vests on May 1, 2026 and each month thereafter (monthly vesting over 48 months), contingent on continued service (footnote F1).
• Shares owned after transaction: not specified in the provided summary of the filing.
• No 10b5-1 plan, tax-withholding, cashless exercise, or late-filing notes indicated in the filing summary.

Context This is a standard equity compensation grant to an executive and should be viewed as part of ongoing incentive pay rather than a bullish open-market purchase or a sale. Because the award vests over four years, the shares will only be obtainable by Agresta gradually as vesting conditions are met. Retail investors often treat new option/RSU grants as a routine compensation action; purchases or sales by insiders are typically more informative about immediate personal market views.